Borgia, Sergio M <br/><br/>
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.  [electronic resource] 

 -  Journal of hepatology  10 2019 
 - 660-665 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1600-0641 
<br/><br/><label>Standard No.: </label>10.1016/j.jhep.2019.05.028  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--administration & dosage<br/>Carbamates--administration & dosage<br/>Drug Combinations<br/>Drug Monitoring--methods<br/>Female<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--complications<br/>Heterocyclic Compounds, 4 or More Rings--administration & dosage<br/>Humans<br/>Kidney Failure, Chronic--complications<br/>Liver Cirrhosis--diagnosis<br/>Male<br/>Middle Aged<br/>Renal Dialysis--methods<br/>Sofosbuvir--administration & dosage<br/>Sustained Virologic Response<br/>Treatment Outcome